Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Ciltacabtagene autoleucel + Talquetamab-tgvs |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ciltacabtagene autoleucel | Carvykti | JNJ-68284528|JNJ-4528|Cilta-cel | TNFRSF17 Immune Cell Therapy 26 | Carvykti (ciltacabtagene autoleucel) is a chimeric antigen receptor T (CAR T)-cell therapy targeting B-cell maturation antigen (BCMA) that may induce cytotoxic immune response against BCMA-expressing tumor cells (PMID: 31622496, PMID: 34175021). Carvykti (ciltacabtagene autoleucel) is FDA approved for use in adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy (FDA.gov). |
Talquetamab-tgvs | Talvey | JNJ64407564|JNJ 64407564|JNJ-64407564 | CD3 Antibody 107 | Talvey (talquetamab-tgvs) is a bispecific antibody that targets CD3 and GPRC5D, potentially resulting in increased immune response against GPRC5D-expressing tumor cells (PMID: 32040549). Talvey (talquetamab-tgvs) is FDA-approved for use in adult patients with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06550895 | Phase II | Daratumumab + Dexamethasone + Lenalidomide Ciltacabtagene autoleucel + Talquetamab-tgvs | A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma (MonumenTAL-8) | Recruiting | USA | AUS | 0 |